Ultragenyx Pharmaceutical EPS beats by $0.79, beats on revenue

• Ultragenyx Pharmaceutical (NASDAQ:RARE): Q4 GAAP EPS of -$0.37 beats by $0.79.
• Revenue of $91.54M (+157.2% Y/Y) beats by $21M.
• Cash, cash equivalents, and marketable debt securities were $1.2B as of Dec. 31, 2020.
• 2021 Crysvita revenue in Ultragenyx territories guidance of $180-$190M reaffirmed.
• Strong Dojolvi launch continues with ~130 patients on reimbursed commercial therapy in the United States.
• Press Release